A b s t r a c t
Acute myeloid leukemia (AML) is characterized by impaired or blocked differentiation of hematopoietic stem cells, resulting in abnormal accumulation of immature precursors and suppression of growth and maturation of cells involved in normal hematopoiesis. Patients with AML are assigned to different prognostic groups by their cytogenetic profiles, and this may influence the therapy. 1, 2 However, 40% to 50% of patients with AML have a normal karyotype by conventional cytogenetic analysis but have a heterogeneous outcome [1] [2] [3] ; thus, additional strategies are required to further evaluate prognosis in this group of patients.
Nucleophosmin (NPM1) is a protein that shuttles between the cytoplasm and nucleus 4 ; it localizes most prominently in the nucleolus. 5 NPM1 functions to promote the biogenesis of the ribosome, control centrosome duplication during the cell cycle, modulate tumor-suppressor transcription factors such as p53, and regulate the function and stability of various nuclear proteins, including ARF and MDM2. 4, [6] [7] [8] [9] [10] Mutations in the NPM1 gene occur in 40% to 50% of AML cases with a normal karyotype (AML-NK). 11 NPM1 mutations occur in exon 12; the most common mutation, mutation A, is a duplication of TCTG at positions 956 and 959. 11 NPM1 mutations generate an extra nuclear export signal motif and cause loss of tryptophan 288 and 290 (or tryptophan 290 alone); as a result, NPM1 accumulates aberrantly in the cytoplasm. [12] [13] [14] Because NPM1 is thought to possess a tumor-suppressor function, any disruption in its cellular localization may be critical for malignant transformation.
NPM1 mutations have been shown to predict favorable prognosis in AML, especially in the absence of FLT3-internal tandem duplication (ITD). 11, [15] [16] [17] [18] [19] However, there have been a few studies with conflicting results about the detection of Upon completion of this activity you will be able to:
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cytoplasmic NPM1 (NPMc+) by immunohistochemical analysis in predicting NPM1 mutations. 11, 12, 20 In this study, we evaluated 57 adult cases of AML-NK for NPM1 expression by immunohistochemical analysis and correlated the staining results with NPM1 mutation status and clinical outcome. 
Materials and Methods

Cases
Immunohistochemical Studies
The value of immunohistochemical studies in predicting NPM1 mutations was assessed through detection of cytoplasmic NPM1 expression in leukemia cells. Immunohistochemical studies were performed with the use of monoclonal mouse antihuman NPM1 antibodies (clone 376) that are suitable for detecting NPM1 in paraffin-embedded sections (DAKO, Carpinteria, CA). These antibodies recognize wild-type NPM1 and the NPM1 leukemia mutants.
All immunohistochemical staining was performed on B-5-fixed, paraffin-embedded bone marrow samples. The sections were deparaffinized by immersing in progressively increasing concentrations of ethanol (70%, 90%, and 100%). Sections were subjected to microwaving/antigen retrieval in 0.1 mmol/L EDTA, pH 8.0, and incubated with antihuman NPM1 monoclonal antibodies (clone 376, dilution 1:400) followed by biotinylated goat antimouse antibodies. Sections were then stained with nova red for cytoplasmic material and counterstained with hematoxylin for nuclear material.
The subcellular distribution of NPM1 (ie, nucleus-restricted [NPMc-] or cytoplasmic staining) was assessed without knowledge of the FAB subtype or molecular findings. The 
Screening for FLT3-ITD and NPM1 Mutations
NPM1 and FLT3-ITD mutation status was evaluated by multiplex reverse transcriptase-polymerase chain reaction (RT-PCR), as previously described. 21 RNA was extracted from the bone marrow mononuclear cells, reverse transcribed into complementary DNA, and then amplified using primers specific for the NPM1 gene and the FLT3 gene, followed by fragment analysis. NPM1 and FLT3 mutations were identified by size.
Statistical Analysis
Statistical analysis was performed for 57 of the 60 cases evaluated by immunohistochemical analysis to evaluate the association between patient characteristics and clinical outcomes. Patient characteristics were calculated as proportions and medians for categorical and continuous variables, respectively. Disease-free survival (DFS) was measured from the establishment of CR until relapse or last follow-up. Overall survival (OS) was measured from diagnosis until death of any cause or last follow-up. Postremission survival (PRS) was measured from CR until death of any cause or last followup. For analysis of association between variables, the Fisher exact test was used for categorical variables, and the MannWhitney U test was used for continuous variables. DFS, PRS, and OS were calculated by using the Kaplan-Meier method. Differences between survival curves were analyzed by using the log-rank test. Multivariate analysis was applied by using the Cox proportional hazards model for DFS, PRS, and OS. Two-sided P values of less than .05 were considered to indicate statistical significance.
Results
Immunohistochemical Studies
The results of the immunohistochemical studies are shown in ❚Table 2❚. All 31 cases with NPMc+ were from patients with NPM1 mutations as determined by RT-PCR; none of the 26 cases with NPMc-carried NPM1 mutations. Leukemic cells from the cell line OCI-AML3, which is known to have NPM1 mutations, showed cytoplasmic NPM1 expression ❚Image 1A❚. The majority (>90%) of mononuclear cells from a healthy bone marrow donor and AML-NK cases with wild-type NPM1 showed clear, NPMc-❚Image 1B❚ and ❚Image 1C❚. NPMc-AML-NK specimens contained only a few NPMc+ leukemic cells, most likely tumor cells undergoing mitosis. The majority (>90%) of leukemic cells from AML-NK cases with mutated NPM1 showed aberrant cytoplasmic NPM1 expression; some NPMc+ samples showed nuclear NPM1 expression, whereas others did not show nuclear NPM1 expression ❚Image 1D❚ and ❚Image 1E❚. The NPMc+ pattern was found in AML specimens of FAB subtypes M1, M2, M4, and M5 but not M0 and M6 (Table 1) .
All 31 NPMc+ cases were easily recognized because they exhibited strong cytoplasmic expression of NPM1 in most leukemic cells, regardless of nuclear expression. Some leukemic cells in NPMc+ samples showed exclusive cytoplasmic expression, whereas some cells showed cytoplasmic and nuclear expression. Cases showing a low blast count (20%-30%) were reviewed by 2 independent observers (J.L. and H.C.). Despite the low number of blasts, staining for these cases was as unambiguous as for cases with a high blast count; they were correctly assigned to the NPM mutational categories by both observers.
Correlation of NPM1 Mutation/NPMc+ With Clinical Features, Immunophenotype, and Treatment Outcome
As shown in Table 1 , cytoplasmic NPM1 expression was correlated with the presence of FLT3-ITD, lack of CD34, and lack of CD7. There was no correlation between NPM1 mutations and other parameters such as age, sex, WBC count, or FAB morphologic subtype.
In NPM1 mutation/NPMc+ in this cohort did not influence DFS (P = .68), PRS (P = .76), or OS (P = .94). Among patients with the NPM1 mutation/NPMc+, the presence of FLT3-ITD did not significantly affect CR rate (P = 1.00) ❚Table 3❚; however, in the absence of FLT3-ITD, patients with mutated NPM1 had significantly longer DFS, PRS, and OS (P < .0001, P = .01, and P = .01, respectively; Table 3 ). Multivariate analysis of DFS, PRS, and OS with NPM1 mutation, FLT3-ITD, and age/treatment as parameters showed that patients with FLT3-ITD had significantly shorter survival than patients without FLT3-ITD (P = .0001, P = .01, and P = .003, respectively) ❚Table 4❚. In addition, multivariate analysis showed that patients who were younger than 60 had a longer OS than patients who were older than 60 (Table 4 ).
Discussion
The relevance of cytogenetic aberrations to the prognosis of AML is well established, and, in recent years, molecular markers, including FLT3-ITD, CEBPA, and NPM1, have been identified that address the variable outcomes of AML-NK. However, inexpensive and accurate detection methods are needed to facilitate introduction of these markers in the diagnostic and prognostic workup of AML. In this study, we have shown that the detection of cytoplasmic NPM1 by immunohistochemical analysis accurately predicts NPM1 mutations. In addition, we confirm that NPMc+ confers a better prognosis in AML-NK, especially in the absence of
FLT3-ITD.
Although mutated NPM1 is implicated in AML development, many studies have shown that NPM1 mutations confer a favorable prognosis in AML-NK cases that cannot be stratified by conventional cytogenetic analysis 11, [15] [16] [17] [18] [19] ; therefore, evaluation of NPM1 mutation status can be used as a prognostic indicator for AML-NK. However, so far only Falini et al 11, 12 were able to show that cytoplasmic expression of NPM1 detected by immunohistochemical analysis correlated with NPM1 mutation. Recently, Konoplev et al 20 showed a lack of correlation between cytoplasmic NPM1 expression and the likelihood of CR and prolonged survival, suggesting that NPM1 mutations, at least as detected using immunohistochemical analysis, may not be a useful prognostic indicator. This is in contrast with our findings that all cases that showed cytoplasmic NPM1 had NPM1 mutations. The inconsistency concerning the ability of immunohistochemical analysis to predict NPM1 mutations may be attributable to the different fixatives used. In addition to the present study, others that found immunohistochemical detection of NPMc+ predicted NPM1 mutations 11, 12 in immunostained B-5-fixed bone marrow samples, whereas the study that did not find a correlation used formalin-fixed marrow samples. 20 Although we can confirm cytoplasmic staining for NPM1 in OCI-AML3 cells when fixed in formalin (data not shown), further comparison of NPM1 immunohistochemical analysis using B-5 with alternative fixatives in an appropriate sample size is needed. Previous studies have stained for nucleolin (C23), another nucleolar antigen, in parallel with NPM1 as a control to provide contrast between nuclear and cytoplasmic staining. 11, 12 Our study did not include this step because hematoxylin staining for nuclear material was sufficient to provide contrast between nuclear and cytoplasmic staining.
Concordant with previous reports, we found NPM1 mutations in 54% of AML-NK cases. 11, [15] [16] [17] [18] [19] Falini et al 11 reported that the NPMc+ pattern can be seen in AML specimens of all FAB subtypes except M3, M4eo, and M7. However, we found the NPMc+ pattern in AML specimens of all FAB subtypes except M0, M6, and M7. Whereas Falini et al 12 observed cytoplasmic NPM1 predominantly in M4 and M5 specimens, we observed cytoplasmic NPM1 predominantly in M2 and M5 cases.
Several groups have suggested that NPM1 and FLT3 mutations are mechanistically linked. 11, 16 As in previous reports, 25% of our AML-NK cases had FLT3-ITD. FLT3-ITD was 5 times more frequent in NPMc+ AML than in NPMc-AML (40% vs 8%), and NPM1 mutation was strongly correlated with FLT3-ITD. Several studies have shown that the survival of patients with AML-NK with FLT3-ITD is significantly inferior to that for patients without FLT3-ITD. [22] [23] [24] [25] [26] Recent studies have also found that patients with NPM1 mutations in the absence of FLT3-ITD have a superior prognosis. 11, [15] [16] [17] [18] [19] Similar to these studies, we found that patients with AML-NK with NPM1 mutations had a higher CR rate, and patients with NPMc+, FLT3-ITD-negative AML-NK had favorable DFS, PRS, and OS.
We also confirmed that in AML-NK, NPM1 mutations are associated with the absence of CD34 expression. 11, 12 In addition, we found that NPM1 mutation in AML-NK is associated with the absence of CD7 expression. CD7 is a pan-T/NK-associated marker that is aberrantly expressed on blast cells in 12% to 37% of AML cases and associated with a poor prognosis. [27] [28] [29] [30] [31] In this study, CD7 was expressed in 38% of the cases; however, we did not find any significant impact of CD7 expression on the clinical outcomes in AML-NK with or without mutated NPM1 in this cohort (data not shown). Future study with a larger sample is required to address the prognostic significance of CD7 in the context of NPM1 mutation status.
Various methods are available for detecting NPM1 mutation and expression in AML-NK, including multiplex RT-PCR, PCR-based assays, 32 and Western blot assay, 33 but this study confirms that immunohistochemical analysis can be used as a surrogate for detecting NPM1 mutations in AML-NK. Immunohistochemical analysis has the advantages that it is inexpensive, rapid, and robust, and it may be warranted in the routine diagnostic and prognostic workup of AML-NK. Because PCR is the only detection method currently available for FLT3-ITD mutations, investigation of rapid and inexpensive detection methods is needed so that NPM1 mutations and FLT3-ITD mutations can be combined to further stratify AML-NK cases.
